Stability study of 188Re-HEDP as a radionuclide therapeutical for bone pain palliation

Abstract

Bisphosphonates are ligands containing the chemical P-C-P bond, which make these molecules resistant to the hydrolytic action of polyphosphatases and hence express high in vivo stability (Body, 2003). Our stability study was performed in order to determine the optimal storage conditions of a single dose radiopharmaceutical, when not applied to a patient immediately after the preparation. Given that the radiopharmaceutical is intended for palliative treatment of patients with malignant diseases, whose condition often does not allow transport to nuclear medicine centers, there is a need for the therapeutic dose to be transported to the institution where the patient is hospitalized (Lepareur et al., 2019). With this study we wanted to examine the conditions in which the transported radiopharmaceutical would remain stable for the longest time, after its separation in syringe as individual patient dose. It is known from the literature that the environmental factors which affect the stability of the rhenium-diphosphonate complexes are temperature and light (Lin et al., 1999).